Eton Pharmaceuticals, Inc. (ETON)

NASDAQ: ETON · IEX Real-Time Price · USD
2.51
-0.04 (-1.57%)
Jun 29, 2022 12:39 PM EDT - Market open
-1.57%
Market Cap 63.31M
Revenue (ttm) 12.11M
Net Income (ttm) -12.40M
Shares Out 25.22M
EPS (ttm) -0.49
PE Ratio n/a
Forward PE 10.00
Dividend n/a
Ex-Dividend Date n/a
Volume 43,864
Open 2.50
Previous Close 2.55
Day's Range 2.48 - 2.59
52-Week Range 2.48 - 6.72
Beta 1.43
Analysts Buy
Price Target 10.20 (+306.4%)
Earnings Date Aug 15, 2022

About ETON

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically impo... [Read more...]

Industry Pharmaceuticals
IPO Date Nov 13, 2018
Employees 17
Stock Exchange NASDAQ
Ticker Symbol ETON
Full Company Profile

Financial Performance

In 2021, ETON's revenue was $23.33 million, an increase of 59,725.64% compared to the previous year's $39,000. Losses were -$1.96 million, -93.01% less than in 2020.

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for ETON stock is "Buy." The 12-month stock price forecast is 10.2, which is an increase of 306.37% from the latest price.

Price Target
$10.2
(306.37% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Eton Pharma Shares Tick Higher After Offloading Hospital Products

Eton Pharmaceuticals Inc (NASDAQ: ETON) has sold its hospital products to Dr. Reddy's Laboratories SA, a subsidiary of Dr. Reddy's Laboratories Ltd (NYSE: RDY), for $50 million. "The sale of our hospita...

Eton Pharmaceuticals Announces Sale of Hospital Products

DEER PARK, Ill., June 24, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, ...

Eton Pharmaceuticals, Inc. (ETON) Reports Q1 Loss, Lags Revenue Estimates

Eton Pharmaceuticals, Inc. (ETON) delivered earnings and revenue surprises of -162.50% and 69.21%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the st...

Eton Pharmaceuticals Reports First Quarter 2022 Financial Results

DEER PARK, Ill., May 12, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, t...

Analysts Estimate Eton Pharmaceuticals, Inc. (ETON) to Report a Decline in Earnings: What to Look Out for

Eton Pharmaceuticals, Inc. (ETON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Eton Pharmaceuticals to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022

DEER PARK, Ill., May 03, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, t...

Eton Pharmaceuticals Appoints James Gruber as Chief Financial Officer

DEER PARK, Ill., April 11, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases,...

Eton Pharmaceuticals Announces FDA Approval of Cysteine Hydrochloride Injection

DEER PARK, Ill., April 11, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases,...

Eton Pharmaceuticals Reports Fourth Quarter 2021 Financial Results

DEER PARK, Ill., March 16, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases,...

Eton Pharmaceuticals and ANI Pharmaceuticals Announce Commercial Availability of Carglumic Acid Tablets, the First an...

DEER PARK, Ill., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases a...

New Strong Sell Stocks for December 14th

SNAX, ETON, AVYA, DLB, and ROCC have been added to the Zacks Rank #5 (Strong Sell) List on December 14, 2021

Other symbols: AVYADLBROCCSNAX

4 Biotech Penny Stocks to Watch With New Catalysts

These biotech penny stocks could be worth watching after recent announcements The post 4 Biotech Penny Stocks to Watch With New Catalysts appeared first on Penny Stocks to Buy, Picks, News and Informati...

Other symbols: COCPCTICOBSV

Eton Pharmaceuticals, Inc. (ETON) Reports Q3 Loss, Misses Revenue Estimates

Eton Pharmaceuticals, Inc. (ETON) delivered earnings and revenue surprises of -71.43% and -74.55%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for th...

Eton Pharmaceuticals Reports Third Quarter Financial Results

DEER PARK, Ill., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, ...

Eton Pharmaceuticals Announces Co-Promotion Agreement with Tolmar Pharmaceuticals for ALKINDI SPRINKLE®

- Tolmar's 62-person sales force will co-promote ALKINDI SPRINKLE® to pediatric endocrinologists - - Tolmar's 62-person sales force will co-promote ALKINDI SPRINKLE® to pediatric endocrinologists -

Eton Pharmaceuticals and Azurity Pharmaceuticals, Inc. Announce FDA Approval of EPRONTIA™ (topiramate) Oral Solution

The first and only FDA-approved ready-to-use liquid topiramate The first and only FDA-approved ready-to-use liquid topiramate

Eton Pharmaceuticals, Inc. (ETON) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Eton Pharmaceuticals, Inc. (ETON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Eton Pharmaceuticals to Report Third Quarter 2021 Financial Results on Monday, November 15, 2021

DEER PARK, Ill., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, ...

Eton Pharmaceuticals Announces Acquisition of Approved Orphan Drug Product Carglumic Acid

-Product is the first generic alternative to one of the highest priced pharmaceutical products in the world -Product is the first generic alternative to one of the highest priced pharmaceutical products...

Eton Pharmaceuticals, Inc. (ETON) Reports Q2 Loss, Misses Revenue Estimates

Eton Pharmaceuticals, Inc. (ETON) delivered earnings and revenue surprises of 42.86% and -19.92%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Eton Pharmaceuticals Reports Second Quarter Financial Results

DEER PARK, Ill., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, ...

Why Is Eton Pharmaceuticals (ETON) Stock Plunging On Monday?

According to an SEC filing, the FDA action date for Eton Pharmaceuticals Inc's (NASDAQ: ETON) antiepileptic topiramate oral solution has been delayed three months to November 6. An FDA decision was expe...

Eton Pharmaceuticals, Inc. (ETON) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Eton Pharmaceuticals, Inc. (ETON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Eton Pharmaceuticals Buys US, Canadian Rights To Zeneo Hydrocortisone Autoinjector

Eton Pharmaceuticals Inc (NASDAQ: ETON) has acquired the U.S. and Canadian rights to Crossject's Zeneo hydrocortisone needleless autoinjector. The product is under development as a rescue treatment for ...